Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Comparison of Efficacy and Safety between Thrombolysis Plus Anticoagulation vs. Anticoagulation Alone for the Treatment of Acute Submassive Pulmonary Embolism: A Systematic Review and Meta-analysis

Author(s): Qingyun Pan, Han Gao, Yingju Wang and Quanfang Chen*

Volume 20, Issue 6, 2022

Published on: 26 August, 2022

Page: [491 - 500] Pages: 10

DOI: 10.2174/1570161120666220811155353

Price: $65

Abstract

Objective: The objective of this study is to compare the efficacy and safety of thrombolysis plus anticoagulant therapy vs. anticoagulant therapy alone in acute submassive pulmonary embolism (PE).

Materials and Methods: The PubMed, Embase, and Cochrane Library databases were searched for randomized clinical trials comparing thrombolytic therapy and anticoagulation vs. anticoagulation alone in acute submassive PE patients from 1 Jan 1980 to 20 Jan 2021, with no drug or dose restrictions. Data on upgraded treatment of clinical deterioration, all-cause mortality, PE recurrence and bleeding events were extracted and analyzed using Revman 5.3 software.

Results: A total of 10 randomized controlled trials involving 1871 patients were included in the study after screening. In terms of efficacy, thrombolysis combined with anticoagulant therapy reduced the need for upgrading treatment (3.6 vs. 10.9%, risk ratio (RR) 0.36, 95% confidence interval (CI) 0.24- 0.54, p<0.00001) and PE recurrence (0.8 vs. 2.9%, RR 0.33, 95% CI 0.16-0.69, p=0.003) in patients with acute submassive PE. Compared with anticoagulant therapy alone, the concomitant use of thrombolysis was associated with lower all-cause mortality (1.3 vs. 3.0%, RR 0.47, 95% CI 0.26-0.87, p=0.02), but it increased minor bleeding rate (31.4 vs. 8.4%, RR 3.71, 95% CI 2.82-4.88, p<0.0001) and major bleeding rate (8.8 vs. 2.6%, RR 3.35, 95%CI 2.03-5.54, p<0.0001).

Conclusion: The use of thrombolysis plus anticoagulant therapy in acute submassive PE was negatively associated with patients requiring escalation of treatment, PE recurrence, and all-cause mortality, but it was positively associated with bleeding.

Keywords: Acute submassive pulmonary embolish, thrombolysis, anticoagulant, therapy, ERS, efficacy, safety.

« Previous Next »
Graphical Abstract

[1]
Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The task force for the diagnosis and management of acute pulmonary embolism of the European society of cardiology (ESC). Eur Heart J 2008; 29(18): 2276-315.
[http://dx.doi.org/10.1093/eurheartj/ehn310] [PMID: 18757870]
[2]
Goy J, Lee J, Levine O, Chaudhry S, Crowther M. Sub-segmental pulmonary embolism in three academic teaching hospitals: A review of management and outcomes. J Thromb Haemost 2015; 13(2): 214-8.
[http://dx.doi.org/10.1111/jth.12803] [PMID: 25442511]
[3]
Costa AF, Basseri H, Sheikh A, Stiell I, Dennie C. The yield of CT pulmonary angiograms to exclude acute pulmonary embolism. Emerg Radiol 2014; 21(2): 133-41.
[http://dx.doi.org/10.1007/s10140-013-1169-x] [PMID: 24185370]
[4]
Carrier M, Righini M, Wells PS, et al. Subsegmental pulmonary embolism diagnosed by computed tomography: Incidence and clinical impli-cations. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost 2010; 8(8): 1716-22.
[http://dx.doi.org/10.1111/j.1538-7836.2010.03938.x] [PMID: 20546118]
[5]
Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism devel-oped in collaboration with the European respiratory society (ERS). Eur Heart J 2020; 41(4): 543-603.
[http://dx.doi.org/10.1093/eurheartj/ehz405] [PMID: 31504429]
[6]
Stein PD, Matta F, Janjua M, Yaekoub AY, Jaweesh F, Alrifai A. Outcome in stable patients with acute pulmonary embolism who had right ventricular enlargement and/or elevated levels of troponin I. Am J Cardiol 2010; 106(4): 558-63.
[http://dx.doi.org/10.1016/j.amjcard.2010.03.071] [PMID: 20691316]
[7]
Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submas-sive pulmonary embolism. N Engl J Med 2002; 347(15): 1143-50.
[http://dx.doi.org/10.1056/NEJMoa021274] [PMID: 12374874]
[8]
Zhao T, Ni J, Hu X, Wang Y, Du X. The efficacy and safety of intermittent low-dose urokinase thrombolysis for the treatment of senile acute intermediate-high-risk pulmonary embolism: A pilot trial. Clin Appl Thromb Hemost 2018; 24(7): 1067-72.
[http://dx.doi.org/10.1177/1076029618758953] [PMID: 29552916]
[9]
Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ 2015; 350(jan02 1): g7647.
[http://dx.doi.org/10.1136/bmj.g7647] [PMID: 25555855]
[10]
Cochrane Handbook for Systematic Reviews of Interventions version 61 (updated September 2020). Cochrane 2020. Available from: www.training.cochrane.org/handbook
[11]
Fasullo S, Scalzo S, Maringhini G, et al. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ven-tricle dysfunction: Comparison of thrombolysis with heparin. Am J Med Sci 2011; 341(1): 33-9.
[http://dx.doi.org/10.1097/MAJ.0b013e3181f1fc3e] [PMID: 20890176]
[12]
Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370(15): 1402-11.
[http://dx.doi.org/10.1056/NEJMoa1302097] [PMID: 24716681]
[13]
Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: Randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341(8844): 507-11.
[http://dx.doi.org/10.1016/0140-6736(93)90274-K] [PMID: 8094768]
[14]
Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: Cardiopulmo-nary outcomes at 3 months: Multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost 2014; 12(4): 459-68.
[http://dx.doi.org/10.1111/jth.12521] [PMID: 24484241]
[15]
Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Tri-al). Am J Cardiol 2013; 111(2): 273-7.
[http://dx.doi.org/10.1016/j.amjcard.2012.09.027] [PMID: 23102885]
[16]
Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute in-termediate-risk pulmonary embolism. Circulation 2014; 129(4): 479-86.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005544] [PMID: 24226805]
[17]
Taherkhani M, Taherkhani A, Hashemi SR, Faghihi Langroodi T, Sadeghi R, Beyranvand M. Thrombolytic-plus-anticoagulant therapy versus anticoagulant-alone therapy in submassive pulmonary thromboembolism (TVASPE study): A randomized clinical trial. J Tehran Heart Cent 2014; 9(3): 104-8.
[PMID: 25870626]
[18]
Becattini C, Agnelli G, Salvi A, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 2010; 125(3): e82-6.
[http://dx.doi.org/10.1016/j.thromres.2009.09.017] [PMID: 19833379]
[19]
Zhang LY, Gao BA, Jin Z, et al. Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute inter-mediate-risk pulmonary embolism. Saudi Med J 2018; 39(11): 1090-5.
[http://dx.doi.org/10.15537/smj.2018.11.22717] [PMID: 30397707]
[20]
Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: A meta-analysis. JAMA 2014; 311(23): 2414-21.
[http://dx.doi.org/10.1001/jama.2014.5990] [PMID: 24938564]
[21]
Chen H, Ren C, Chen H. Thrombolysis versus anticoagulation for the initial treatment of moderate pulmonary embolism: A meta-analysis of randomized controlled trials. Respir Care 2014; 59(12): 1880-7.
[http://dx.doi.org/10.4187/respcare.03197] [PMID: 25269681]
[22]
Gao GY, Yang P, Liu M, et al. Thrombolysis for acute intermediate-risk pulmonary embolism: A meta-analysis. Thromb Res 2015; 136(5): 932-7.
[http://dx.doi.org/10.1016/j.thromres.2015.09.012] [PMID: 26384442]
[23]
Nakamura S, Takano H, Kubota Y, Asai K, Shimizu W. Impact of the efficacy of thrombolytic therapy on the mortality of patients with acute submassive pulmonary embolism: A meta-analysis. J Thromb Haemost 2014; 12(7): 1086-95.
[http://dx.doi.org/10.1111/jth.12608] [PMID: 24829097]
[24]
Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: A meta-analysis. Ann Intern Med 2003; 139(11): 893-900.
[http://dx.doi.org/10.7326/0003-4819-139-11-200312020-00007] [PMID: 14644891]
[25]
Konstantinides SV, Vicaut E, Danays T, et al. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. J Am Coll Cardiol 2017; 69(12): 1536-44.
[http://dx.doi.org/10.1016/j.jacc.2016.12.039] [PMID: 28335835]
[26]
Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013; 368(15): 1379-87.
[http://dx.doi.org/10.1056/NEJMoa1301092] [PMID: 23473396]
[27]
van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004; (4): CD001100.
[PMID: 15495007]

Rights & Permissions Print Cite
Article Metrics
40
2
© 2024 Bentham Science Publishers | Privacy Policy